The introduction of new treatment options, namely GLP‐1 analogues and SGLT‐2 inhibitors (market authorization granted by European Medicines Agency respectively in 2006 and 201319), as well as second‐generation BIs, Gla‐300 and degludec (which entered the market respectively in 2015 and 2013), makes it interesting to compare glycemic control in T2D naïve insulin users at EOS and T2D prevalent users at index. Here, SLC5A2 is linked to type 2 diabetes mellitus.